Clinical Evidence in Humans The topical evidence base is unusually robust for a research peptide: Facial aging study (71 women, 12 weeks): A GHK-Cu facial cream documented increased skin density and thickness, reduced laxity, improved clarity, and reduced fine lines and depth of wrinkles (PMID 26236730)
Cancer immunotherapy using checkpoint blockade
The distinction between temporary nausea and permanent gastroparesis represents a fundamental failure in risk communication that left patients unable to make informed treatment decisions
By this point, 85% of users report minimal to no side effects
Most patients at The Dermatology and Laser Group receive between two and four vials total for facial rejuvenation, though patients addressing significant volume loss especially from weight loss or aging may benefit from additional vials
Protecting patient privacy requires implementing a multi-layered security model